IL-37 belongs to the IL-1 family of cytokines. It was named IL-1F7 when it was first discovered. It has 5 different subtypes (IL37a~e). Studies have confirmed that IL-37 can inhibit the production of pro-inflammatory cytokines in a variety of immune cells, thereby regulating the innate immune response; in addition, IL-37 can induce inflammatory colitis, arthritis, and pancreatitis induced by exogenous stimulation. Disease has a certain protective effect. In short, IL-37 can play an inhibitory role in a variety of inflammation-related diseases and is a new type of inflammation inhibitor.
As an inflammatory inhibitor, IL-37 plays an important regulatory role in the innate immune response and can participate in the occurrence and development of a variety of inflammatory diseases. It provides a new basis and therapeutic target for the diagnosis and treatment of inflammatory diseases. Therefore, it has huge research value and clinical application potential. In recent years, more and more research results on IL-37 have been published. With the deepening of its research, the role of IL-37 in infectious diseases, autoimmune deficiencies and tumors, etc. More reveals have been made, and preliminary research progress has been made in the molecular mechanisms of IL-37 receptors and signal transduction. However, the specific regulation mechanism of the various IL-37 subtypes on the disease is not yet fully understood, and further research and verification are still needed.